{"id":41948,"date":"2025-12-18T09:31:00","date_gmt":"2025-12-18T02:31:00","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=41948"},"modified":"2025-12-18T09:31:00","modified_gmt":"2025-12-18T02:31:00","slug":"corestemchemon-advances-toward-als-stem-cell-commercialization-with-regulatory-progress-in-korea-and-nsf-backed-u-s-expansion","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=41948","title":{"rendered":"CorestemChemon Advances Toward ALS Stem Cell Commercialization with Regulatory Progress in Korea and NSF-Backed U.S. Expansion"},"content":{"rendered":"<p><span class=\"legendSpanClass\"><span class=\"xn-location\">SEOUL, South Korea<\/span>, Dec. 18, 2025 \/PRNewswire\/ &#8212; <b>CorestemChemon (KOSDAQ: 166480) <\/b>is entering a critical late-stage phase in the commercialization of its ALS stem cell therapy, Neuronata-R. The company attributes this momentum to advanced domestic regulatory review in Korea, entry into an NSF-supported regenerative medicine ecosystem in <span class=\"xn-location\">the United States<\/span>, secured commercialization capital, and a sizable open-market share purchase by the CEO.<\/span><\/p>\n<p><b>Key Strategic Updates<\/b><\/p>\n<ul type=\"disc\">\n<li>Progressing through an advanced MFDS review of a precision-targeted ALS subgroup strategy in Korea<\/li>\n<li>Selected to participate in the NSF-supported U.S. regenerative medicine innovation engine<\/li>\n<li><span class=\"xn-money\">KRW 26.1 billion<\/span> in commercialization capital secured, supporting manufacturing readiness and global regulatory preparation<\/li>\n<li>Approximately <span class=\"xn-money\">KRW 1.7 billion<\/span> open-market share purchase by the CEO, reinforcing management conviction and shareholder alignment<\/li>\n<\/ul>\n<p><b>Regulatory Progress and Commercial Readiness in Korea<\/b><\/p>\n<p>In Korea, Neuronata-R is undergoing a product license modification review by the Ministry of Food and Drug Safety (MFDS). Following mixed efficacy results in the overall patient population in the Phase 3 ALSUMMIT trial, CorestemChemon refined its regulatory strategy to focus on a clinically defined &#8220;slow progressor&#8221; subgroup.<\/p>\n<p>Post-hoc analyses in this subgroup showed clinically meaningful and internally consistent signals, including maintenance of ALS Functional Rating Scale-Revised (ALSFRS-R) scores, stabilization of slow vital capacity (SVC), and favorable trends in neurofilament light chain (NfL) biomarkers. The company believes these findings have supported a more structured and focused regulatory dialogue with the MFDS.<\/p>\n<p>The company expects this precision-targeted approach to further clarify the domestic regulatory pathway, while preserving the option for initial commercialization upon potential approval. A favorable MFDS decision would enable domestic market entry and generation of real-world evidence (RWE), which could support future global regulatory strategies. The company expects a final regulatory decision in Korea before the first quarter of 2026.<\/p>\n<p><b>Entry into NSF-Supported U.S. Regenerative Medicine Ecosystem<\/b><\/p>\n<p>CorestemChemon has been selected to join the Piedmont Triad Regenerative Medicine Innovation Engine, a U.S. regional innovation cluster supported by the National Science Foundation (NSF). The company stated that it is the first Korean biotechnology firm to be included in an NSF-backed regenerative medicine ecosystem.<\/p>\n<p>The selection was initiated by the Wake Forest Institute for Regenerative Medicine (WFIRM), which cited the scientific robustness of Neuronata-R&#8217;s Phase 3 clinical dataset and the consistency observed in long-term real-world follow-up data. Participation in the NSF Engine is expected to provide access to translational research capabilities, manufacturing resources, and a broader regulatory network.<\/p>\n<p>To align more closely with this ecosystem, CorestemChemon plans to relocate its U.S. subsidiary to <span class=\"xn-location\">North Carolina<\/span>. The company intends to leverage the cluster as a platform for regulatory engagement with the U.S. Food and Drug Administration (FDA), targeting submission of a Biologics License Application (BLA) in the third quarter of 2026.<\/p>\n<p><b>Commercialization Funding and Financial Position<\/b><\/p>\n<p>To support commercialization readiness following potential domestic approval, CorestemChemon recently completed a rights offering, raising <span class=\"xn-money\">KRW 26.1 billion<\/span> in operating capital (approximately <span class=\"xn-money\">USD 17.8 million<\/span>, based on recent exchange rates). The proceeds are allocated to upgrading production facilities, establishing commercial-scale manufacturing systems, and preparing for both domestic and global regulatory processes.<\/p>\n<p>The company expects the capital raise to strengthen its financial position and reduce execution risk associated with manufacturing scale-up and regulatory preparation, while addressing near-term funding concerns.<\/p>\n<p><b>CEO Share Purchase Reinforces Management Conviction<\/b><\/p>\n<p>In a move widely interpreted as reinforcing market confidence, CEO <span class=\"xn-person\">Yang Gil<\/span>-ahn recently executed a large-scale open-market share purchase. Over a two-week period, he acquired more than one million shares, representing an investment of approximately <span class=\"xn-money\">KRW 1.7 billion<\/span> (approximately <span class=\"xn-money\">USD 1.2 million<\/span>, based on recent exchange rates).<\/p>\n<p>The purchase coincided with the submission of supplementary regulatory materials to the MFDS and is viewed as a signal of management&#8217;s conviction at a key regulatory inflection point. Following the transaction, the combined ownership stake of the controlling shareholder group increased to 10.32%, further strengthening alignment between management and shareholders.<\/p>\n<p><b>Outlook<\/b><\/p>\n<p>With continued domestic regulatory progress, secured commercialization capital, and a defined U.S. regulatory pathway supported by NSF-backed infrastructure, CorestemChemon is positioning Neuronata-R to transition from late-stage development toward initial market entry and real-world evidence generation. The company expects these milestones to support broader global expansion and long-term value creation.<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">SEOUL, South Korea<\/span>, Dec. 18, 2025 \/PRNewswire\/ &#8212; <b>CorestemChemon (KOSDAQ: 166480) <\/b>is entering a critical late-stage phase in the commercialization of its ALS stem cell therapy, Neuronata-R. The company attributes this momentum to advanced domestic regulatory review in Korea, entry into an NSF-supported regenerative medicine ecosystem in <span class=\"xn-location\">the United States<\/span>, secured commercialization capital, and a sizable open-market share purchase by the CEO.<\/span><\/p>\n<p><b>Key Strategic Updates<\/b><\/p>\n<ul type=\"disc\">\n<li>Progressing through an advanced MFDS review of a precision-targeted ALS subgroup strategy in Korea<\/li>\n<li>Selected to participate in the NSF-supported U.S. regenerative medicine innovation engine<\/li>\n<li><span class=\"xn-money\">KRW 26.1 billion<\/span> in commercialization capital secured, supporting manufacturing readiness and global regulatory preparation<\/li>\n<li>Approximately <span class=\"xn-money\">KRW 1.7 billion<\/span> open-market share purchase by the CEO, reinforcing management conviction and shareholder alignment<\/li>\n<\/ul>\n<p><b>Regulatory Progress and Commercial Readiness in Korea<\/b><\/p>\n<p>In Korea, Neuronata-R is undergoing a product license modification review by the Ministry of Food and Drug Safety (MFDS). Following mixed efficacy results in the overall patient population in the Phase 3 ALSUMMIT trial, CorestemChemon refined its regulatory strategy to focus on a clinically defined &#8220;slow progressor&#8221; subgroup.<\/p>\n<p>Post-hoc analyses in this subgroup showed clinically meaningful and internally consistent signals, including maintenance of ALS Functional Rating Scale-Revised (ALSFRS-R) scores, stabilization of slow vital capacity (SVC), and favorable trends in neurofilament light chain (NfL) biomarkers. The company believes these findings have supported a more structured and focused regulatory dialogue with the MFDS.<\/p>\n<p>The company expects this precision-targeted approach to further clarify the domestic regulatory pathway, while preserving the option for initial commercialization upon potential approval. A favorable MFDS decision would enable domestic market entry and generation of real-world evidence (RWE), which could support future global regulatory strategies. The company expects a final regulatory decision in Korea before the first quarter of 2026.<\/p>\n<p><b>Entry into NSF-Supported U.S. Regenerative Medicine Ecosystem<\/b><\/p>\n<p>CorestemChemon has been selected to join the Piedmont Triad Regenerative Medicine Innovation Engine, a U.S. regional innovation cluster supported by the National Science Foundation (NSF). The company stated that it is the first Korean biotechnology firm to be included in an NSF-backed regenerative medicine ecosystem.<\/p>\n<p>The selection was initiated by the Wake Forest Institute for Regenerative Medicine (WFIRM), which cited the scientific robustness of Neuronata-R&#8217;s Phase 3 clinical dataset and the consistency observed in long-term real-world follow-up data. Participation in the NSF Engine is expected to provide access to translational research capabilities, manufacturing resources, and a broader regulatory network.<\/p>\n<p>To align more closely with this ecosystem, CorestemChemon plans to relocate its U.S. subsidiary to <span class=\"xn-location\">North Carolina<\/span>. The company intends to leverage the cluster as a platform for regulatory engagement with the U.S. Food and Drug Administration (FDA), targeting submission of a Biologics License Application (BLA) in the third quarter of 2026.<\/p>\n<p><b>Commercialization Funding and Financial Position<\/b><\/p>\n<p>To support commercialization readiness following potential domestic approval, CorestemChemon recently completed a rights offering, raising <span class=\"xn-money\">KRW 26.1 billion<\/span> in operating capital (approximately <span class=\"xn-money\">USD 17.8 million<\/span>, based on recent exchange rates). The proceeds are allocated to upgrading production facilities, establishing commercial-scale manufacturing systems, and preparing for both domestic and global regulatory processes.<\/p>\n<p>The company expects the capital raise to strengthen its financial position and reduce execution risk associated with manufacturing scale-up and regulatory preparation, while addressing near-term funding concerns.<\/p>\n<p><b>CEO Share Purchase Reinforces Management Conviction<\/b><\/p>\n<p>In a move widely interpreted as reinforcing market confidence, CEO <span class=\"xn-person\">Yang Gil<\/span>-ahn recently executed a large-scale open-market share purchase. Over a two-week period, he acquired more than one million shares, representing an investment of approximately <span class=\"xn-money\">KRW 1.7 billion<\/span> (approximately <span class=\"xn-money\">USD 1.2 million<\/span>, based on recent exchange rates).<\/p>\n<p>The purchase coincided with the submission of supplementary regulatory materials to the MFDS and is viewed as a signal of management&#8217;s conviction at a key regulatory inflection point. Following the transaction, the combined ownership stake of the controlling shareholder group increased to 10.32%, further strengthening alignment between management and shareholders.<\/p>\n<p><b>Outlook<\/b><\/p>\n<p>With continued domestic regulatory progress, secured commercialization capital, and a defined U.S. regulatory pathway supported by NSF-backed infrastructure, CorestemChemon is positioning Neuronata-R to transition from late-stage development toward initial market entry and real-world evidence generation. The company expects these milestones to support broader global expansion and long-term value creation.<\/p>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[1],"tags":[],"class_list":["post-41948","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/41948","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=41948"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/41948\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=41948"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=41948"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=41948"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}